CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
10220 ETCTN A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors Adult CIRB - Early Phase Emphasis
10221 ETCTN A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in patients with advanced solid tumors Adult CIRB - Early Phase Emphasis
10222 ETCTN A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors Adult CIRB - Early Phase Emphasis
10231 NCORP-National Institutes of Health NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study Adult CIRB - Late Phase Emphasis
10237 et A Phase 1 Study of TAK-243 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes with Increased Blasts Adult CIRB - Early Phase Emphasis
10240 ETCTN Phase II Study of XL184 (cabozantinib) in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after One Prior VEGFR-Targeted Therapy Adult CIRB - Early Phase Emphasis
10246 ETCTN A Phase 1 Study of MLN4924 (pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Adult CIRB - Early Phase Emphasis
10247 ETCTN A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia Adult CIRB - Early Phase Emphasis
10249 ETCTN MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial Adult CIRB - Early Phase Emphasis
10250 ETCTN A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma Adult CIRB - Early Phase Emphasis